You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics of anaplastict thyroid cancer (ATC) patients treated with pembrolizumab added as a salvage therapy to kinase inhibitor therapy

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

  N = 12
Median Age at treatment start, years (range) 60 (47–84)
Gender, n (%)
 Men  Women 8 (67) 4 (33)
Ethnicity, n (%)
  Caucasian   Asian   Black 9 (75) 2 (16) 1 (9)
Stage at Diagnosis, n (%)
  IVA   IVB   IVC 0 (0) 3 (25) 9 (75)
Pathology, n (%)
  ATC only   Papillary thyroid cancer + ATC   Poorly differentiated thyroid cancer + ATC   Follicular thyroid cancer +ATC 4 (33) 4 (33) 3 (25) 1 (9)
PD-L1 status, n (%)   < 10%  11–50%  51–100% 10 (83) 2 (20) 4 (40) 4 (40)
Performance Status, n (%)
  ECOG 0   ECOG 1   ECOG 2 2 (16) 6 (50) 4 (33)
Previous Treatment for ATC, n (%)a
  Surgery, n (%)   Radiation/chemosensitizing, n (%)   Bridging Chemotherapy, n (%)b 5 (41) 6 (50) 3 (25)
Targeted therapyc, n (%)
  Lenvatinib   Dabrafenib + trametinib   Trametinib alone 5 (41) 6 (50) 1 (9)
  1. aPatients received more than 1 modality of therapy
  2. bChemotherapy as a bridging therapy while awaiting targeted therapy
  3. cAll patients with BRAFV600E mutations were treated with dabrafenib + trametinib